Valeant to acquire Medicis Pharmaceutical in $2.6 billion deal

Valeant Pharmaceuticals International Inc.

Valeant Pharmaceuticals International Inc.

Valeant Pharmaceuticals International Inc. informed that it would buy Medicis Pharmaceutical Corp. for $2.6 billion in cash. The deal will add Botox competitor Dysport and other skin care drugs to the company’s portfolio. Valeant, the largest publicly traded drug maker in Canada, intends to expand its dermatological products. In addition, the acquisition of Medicis is a part of the Valeant’s acquisition strategy which slipped on last year’s bid for Cephalon Inc.

The acquisition of Medicis

Valeant informed yesterday that it would pay $44 in cash for each Medicis’ share, which is a 39 percent increase compared to the closing price on the 31st of August on the New York Stock Exchange. The acquisition of Medicis will be finalized in the first half of 2013, according to Valeant, the Montreal-based company.

The acquisition of Medicis would be the largest deal for Valeant, Canada’s largest publicly traded drug maker, since it was created in a merger of Canada’s Biovail Corp. and an Aliso Viejo, a predecessor company, in 2010. Since Michael Pearson was named a new CEO at the company in 2008, Valeant has made about 50 acquisitions of companies and assets which were aimed at increasing the company’s dermatology business.

Michael Pearson, CEO at Valeant and the company’s chairman as well, said: “The acquisition of Medicis represents a significant next step in our journey to become the leader in dermatology by strengthening Valeant’s presence in acne, actinic keratosis, aesthetic injectables and antivirals, among others.”

Valeant’s officials are convinced that the acquisition of Medicis, which is the biggest since a failed $5.7 billion bid to acquire specialty drug maker Cephalon Inc. in 2011, will add to the company’s earnings per share just from the beginning. The acquisition of Medicis is expected to generate more than $1.7 billion in pro forma revenue for the combined company’s dermatology and aesthetics businesses within the United States just this year. However the deal is to close in the first half of 2013, is likely to yield cost synergies at an annual rate of at least $225 million within 6 months of the completion of the acquisition. According to data, Medicis had about $721 million in revenue in 2011, while Valeant reported $2.5 billion in sales.

The acquisition of Medicis is subject to conditions that include, inter alia, approval by Medicis’ shareholders.

Valeant’s acquisition strategy

Michael Pearson prefers expansion through acquisition than spending on research. And since 2010 the company has been almost on a “purchase spree”. Valeant’s acquisition strategy is the main instrument of the company’s expansion these days.

The Valeant’s acquisition strategy can be described as a strategy aiming at mixing larger deals with smaller ones, according to Michael Pearson. He has added that the Valeant’s acquisition strategy focuses on ophthalmology and dermatology; the company has concentrated on treatments for both central nervous system and skin diseases as well.

Clearly dermatology is the biggest business for Valeant. The company has been working on growing it, focusing mainly on the U.S. market. According to Michael Pearson’s expectations, the dermatology business will contribute roughly half of Valeant’s revenue once the acquisition of Medicis closes. The U.S. dermatology business was a 27 percent of Valeant’s revenue for the three month ended June; compared to 18 percent in a previous year.

Valeant acquired U.S.-based Pedinol Pharmacal Inc. in April; the company purchased some assets from University Medical in May. As it has been stated by Michael Pearson, more deals are likely in 2012. In addition, Valeant is strongly interested in opportunities in Southeast Asia. The Valeant’s acquisition strategy has been modified this way as the company wants be more involved in that part of the world.

Anna Domanska
Anna Domanska is an Industry Leaders Magazine author possessing wide-range of knowledge for Business News. She is an avid reader and writer of Business and CEO Magazines and a rigorous follower of Business Leaders.

Recent Posts

Supply chain crisis bad news for automotive industry leaders

Supply chain crisis bad news for automotive industry leaders

The world’s biggest car companies are on track to lose production of 7.7 million vehicles in 2021. The forecast advices automakers on supply chain and other issues.
2 days ago
Scammers dupe Apple fans with free bitcoin lure

Scammers dupe Apple fans with free bitcoin lure

Savvy scammers used a fake event stream, a fake Apple website, and the promise of free bitcoin to lure fans into opening up their wallets.
3 days ago
Japan’s MUFG offloads Union Bank to U.S. Bancorp for $7.3 billion

Japan’s MUFG offloads Union Bank to U.S. Bancorp for $7.3 billion

The total amount of cash to be received as part of MUFG Union Bank’s sale to Bancorp is $7.3 billion (800 billion yen).
4 days ago
Evergrande: A black swan event that could spook markets

Evergrande: A black swan event that could spook markets

EverGrande is now known as the “world’s most indebted property developer” and serves as a symbol of corporate excess.
5 days ago
Moderna vaccine more effective than Pfizer, study says

Moderna vaccine more effective than Pfizer, study says

Moderna’s Covid-19 vaccine does a slightly better job of preventing coronavirus-related hospitalizations and emergency department visits.
7 days ago
iPhone 13 and iPhone 13 Pro: Specifications, Release Date, Features and much more

iPhone 13 and iPhone 13 Pro: Specifications, Release Date, Features and much more

Apple iPhone 13 Pro and iPhone 13 Pro Max can be a hit with its ever new technology A15 Bionic chip and other cool profound features.
1 week ago